Not All Missed Doses Are the Same: Sustained NNRTI Treatment Interruptions Predict HIV Rebound at Low-to-Moderate Adherence Levels - Parienti, Jean-Jacques; Das-Douglas, Moupali; Massari, Véronique; Guzman, David; Deeks, Steven G.; Verdon, Renaud; Bangsberg, David R. (PloS one, 2008)
Keywords: Acquired immune deficiency syndrome; Adhesion; Adult; Adults; AIDS; Anti-HIV Agents - therapeutic use; Antiretroviral agents; Antiretroviral drugs; Antiretroviral therapy; Antiretroviral Therapy, Highly Active; Biological products industry; Case-Control Studies; Clinical trials; Cohort Studies; Confidence intervals; Disease prevention; DNA polymerases; Drug dosages; Drug resistance; Drug therapy; Drugs; Efavirenz; Epidemiology; Female; Health care access; Health risks; Highly active antiretroviral therapy; HIV; HIV - metabolism; HIV Infections - drug therapy; Hospitals; Human immunodeficiency virus; Humans; Infections; Infectious diseases; Infectious Diseases/HIV Infection and AIDS; Interruption; Male; Microelectromechanical systems; Middle Aged; Monitoring systems; Nevirapine; Odds Ratio; Patient Compliance; Plasma; Public Health and Epidemiology/Infectious Diseases; Reverse Transcriptase Inhibitors - pharmacology; Ribonucleic acid; Risk assessment; Risk reduction; RNA; RNA, Viral - metabolism; RNA-directed DNA polymerase; Studies; Therapy; Virology/Antivirals, including Modes of Action and Resistance; San Francisco California; California; France; United States--US; Massachusetts